Transplacental Therapeutic Drug Monitoring in Pregnant Women with Fetal Tachyarrhythmia Using HPLC-MS/MS

Transplacental Therapeutic Drug Monitoring in Pregnant Women with Fetal Tachyarrhythmia Using HPLC-MS/MS

Fetal arrhythmia develops in 0.1–5% of pregnancies and may cause fetal heart failure and fetal hydrops, thus increasing fetal, neonatal, and infant mortality. The timely initiation of transplacental antiarrhythmic therapy (ART) promotes the conversion of fetal tachycardia to sinus rhythm and the reg...

Full description

Bibliographic Details
Main Authors: Natalia Starodubtseva, Svetlana Kindysheva, Alyona Potapova, Evgenii Kukaev, Zulfiya Khodzhaeva, Ekaterina Bockeria, Vitaliy Chagovets, Vladimir Frankevich, Gennady Sukhikh
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:International Journal of Molecular Sciences
Subjects:
fetal tachyarrhythmia
therapeutic drug monitoring
digoxin
sotalol
mass spectrometry
high performance liquid chromatography with mass spectrometry
Online Access:https://www.mdpi.com/1422-0067/24/3/1848

Internet

https://www.mdpi.com/1422-0067/24/3/1848

Similar Items